Roche Holding AG $RHHBY Position Boosted by First Command Advisory Services Inc.

First Command Advisory Services Inc. lifted its position in Roche Holding AG (OTCMKTS:RHHBY) by 188.7% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 37,694 shares of the company’s stock after buying an additional 24,639 shares during the period. First Command Advisory Services Inc.’s holdings in Roche were worth $1,956,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the company. McIlrath & Eck LLC bought a new stake in Roche in the first quarter worth about $39,000. Renasant Bank bought a new position in shares of Roche during the 2nd quarter valued at about $210,000. Woodstock Corp bought a new position in shares of Roche during the 3rd quarter valued at about $245,000. Enterprise Financial Services Corp grew its stake in shares of Roche by 6.6% in the 1st quarter. Enterprise Financial Services Corp now owns 5,576 shares of the company’s stock worth $277,000 after purchasing an additional 345 shares during the last quarter. Finally, Archer Investment Corp grew its stake in shares of Roche by 7.7% in the 1st quarter. Archer Investment Corp now owns 5,598 shares of the company’s stock worth $278,000 after purchasing an additional 398 shares during the last quarter.

Roche Trading Down 0.8%

Shares of RHHBY stock opened at $60.57 on Thursday. Roche Holding AG has a 1-year low of $44.57 and a 1-year high of $61.75. The company has a current ratio of 1.23, a quick ratio of 0.95 and a debt-to-equity ratio of 0.69. The stock’s fifty day simple moving average is $56.28 and its 200-day simple moving average is $53.97.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. HSBC reiterated a “hold” rating on shares of Roche in a report on Thursday, September 10th. Deutsche Bank raised Roche from a “hold” rating to a “buy” rating in a report on Friday, October 23rd. Royal Bank Of Canada started coverage on Roche in a report on Tuesday, September 8th. They issued an “outperform” rating on the stock. Zacks Research raised Roche from a “strong sell” rating to a “hold” rating in a research report on Monday, August 24th. Finally, Morgan Stanley raised Roche from an “equal weight” rating to an “overweight” rating and set a $63.00 target price for the company in a report on Friday, August 7th. Eight analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $60.00.

Roche Company Profile

Roche is a Swiss healthcare company with two main businesses: pharmaceuticals and diagnostics. Founded in Basel in 1896, the company develops and commercializes medicines and provides diagnostic tests, instruments, and digital health solutions. Its pharmaceutical research and products span areas including oncology, immunology, neuroscience, ophthalmology, and infectious diseases. Its diagnostics business serves clinical laboratories, hospitals, healthcare providers, and patients with tools used to detect and monitor a range of medical conditions.